Global Ascites Market

Ascites Comprehensive Study by Type (Exudate Ascites, Transudative Ascites), Application (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostics Centers, Others), Diagnosis (Angiography, Ultrasound, Laparoscopy, CT scan, Others), Symptoms (Abdominal Pain and Bloating, Shortness of Breath, Liver Failure) Players and Region - Global Market Outlook to 2028

Ascites Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Ascites occurs when fluid accumulates in the abdomen. This start occurs between two membrane layers that together make up the peritoneum, it is a smooth sac that contains the body’s organ. Many diseases are responsible for causing ascites such as tuberculosis, kidney disease, pancreatitis, and an underactive thyroid. Currently no satisfactory treatment for patients who have cirrhosis as well as a form of ascites that is resistant to diuretics.This growth is primarily driven by Rise in Prevalence of Liver Cirrhosis .

AttributesDetails
Study Period201-2028
Base Year2022
Forecast Period2023-2028
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Diseases & Therapeutic Areas sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Sofinnova (United States), PharmaCyte (United States), Biotech Inc. (United States), Sequana Medical NV (Belgium), BioVie Inc. (United States), Becton (United States), Dickinson and Company (United States), GI Supply (United States), QED Bioscience Inc. (United States) and Fresenius SE & Co. KGaA (Germany), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In August 2022, biotechnology company PharmaCyte Biotech, Inc. uses its signature live-cell encapsulation technology Cell-in-a-Box, the PharmaCyte and Iroquois Master Fund Ltd, to develop cell therapies for cancer, diabetes, and malignant ascites. focused. As beneficial owners of approximately 6.7% of the outstanding shares of PharmaCyte common stock, its affiliates have signed a cooperative agreement that includes the nomination of two Iroquois director-nominees to PharmaCyte's restructured board of directors.
In Nov 2018, Sequana Medical Announced Its Focus On The Development Of Innovation Solutions For The Management Of Liver Disease, Malignant Ascites By Raising New Funds Through Initial Public Offering With Admission Of All Of Its Shares On The Regulated Market Of Euronext Brussels.The Global Ascites Market Is Highly Competitive And Consists Of Some Key Players. In Terms Of Market Share, Few Of The Key Players Presently Dominate The Global Market. The Players Are Focusing On Defining More Number Of Treatments And Medicines. And Also Companies Are Investing Research & Development To Find New Innovations.

Influencing Trend:
High Growth in Ultrasound Segment

Market Growth Drivers:
Rise in Prevalence of Liver Cirrhosis, Increasing Number of Patients Suffering From Liver Cirrhosis and Rise in Cancer Cases

Challenges:
Unavailability of Appropriate Treatments

Restraints:
Increasing Complications Related With Ascites Treatment Is One of the Reasons Likely To Restrain the Global Ascites Market

Opportunities:
High Alcohol Consumption and Obesity Are the Potential Factors Which Expected High Growth in the Ascites Market

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Ascites Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Ascites Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Ascites players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Ascites Study Sheds Light on
— The Ascites Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Ascites industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Ascites industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Exudate Ascites
  • Transudative Ascites
By Application
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Diagnostics Centers
  • Others
By Diagnosis
  • Angiography
  • Ultrasound
  • Laparoscopy
  • CT scan
  • Others

By Symptoms
  • Abdominal Pain and Bloating
  • Shortness of Breath
  • Liver Failure

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Prevalence of Liver Cirrhosis
      • 3.2.2. Increasing Number of Patients Suffering From Liver Cirrhosis
      • 3.2.3. Rise in Cancer Cases
    • 3.3. Market Challenges
      • 3.3.1. Unavailability of Appropriate Treatments
    • 3.4. Market Trends
      • 3.4.1. High Growth in Ultrasound Segment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ascites, by Type, Application, Diagnosis, Symptoms and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Ascites (Value)
      • 5.2.1. Global Ascites by: Type (Value)
        • 5.2.1.1. Exudate Ascites
        • 5.2.1.2. Transudative Ascites
      • 5.2.2. Global Ascites by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Surgical Centers
        • 5.2.2.4. Diagnostics Centers
        • 5.2.2.5. Others
      • 5.2.3. Global Ascites by: Diagnosis (Value)
        • 5.2.3.1. Angiography
        • 5.2.3.2. Ultrasound
        • 5.2.3.3. Laparoscopy
        • 5.2.3.4. CT scan
        • 5.2.3.5. Others
      • 5.2.4. Global Ascites by: Symptoms (Value)
        • 5.2.4.1. Abdominal Pain and Bloating
        • 5.2.4.2. Shortness of Breath
        • 5.2.4.3. Liver Failure
      • 5.2.5. Global Ascites Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Ascites: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sofinnova (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. PharmaCyte (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biotech Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sequana Medical NV (Belgium)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BioVie Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Becton (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Dickinson and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GI Supply (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. QED Bioscience Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Fresenius SE & Co. KGaA (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Ascites Sale, by Type, Application, Diagnosis, Symptoms and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Ascites (Value)
      • 7.2.1. Global Ascites by: Type (Value)
        • 7.2.1.1. Exudate Ascites
        • 7.2.1.2. Transudative Ascites
      • 7.2.2. Global Ascites by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Surgical Centers
        • 7.2.2.4. Diagnostics Centers
        • 7.2.2.5. Others
      • 7.2.3. Global Ascites by: Diagnosis (Value)
        • 7.2.3.1. Angiography
        • 7.2.3.2. Ultrasound
        • 7.2.3.3. Laparoscopy
        • 7.2.3.4. CT scan
        • 7.2.3.5. Others
      • 7.2.4. Global Ascites by: Symptoms (Value)
        • 7.2.4.1. Abdominal Pain and Bloating
        • 7.2.4.2. Shortness of Breath
        • 7.2.4.3. Liver Failure
      • 7.2.5. Global Ascites Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ascites: by Type(USD Million)
  • Table 2. Ascites Exudate Ascites , by Region USD Million (2017-2022)
  • Table 3. Ascites Transudative Ascites , by Region USD Million (2017-2022)
  • Table 4. Ascites: by Application(USD Million)
  • Table 5. Ascites Hospitals , by Region USD Million (2017-2022)
  • Table 6. Ascites Clinics , by Region USD Million (2017-2022)
  • Table 7. Ascites Ambulatory Surgical Centers , by Region USD Million (2017-2022)
  • Table 8. Ascites Diagnostics Centers , by Region USD Million (2017-2022)
  • Table 9. Ascites Others , by Region USD Million (2017-2022)
  • Table 10. Ascites: by Diagnosis(USD Million)
  • Table 11. Ascites Angiography , by Region USD Million (2017-2022)
  • Table 12. Ascites Ultrasound , by Region USD Million (2017-2022)
  • Table 13. Ascites Laparoscopy , by Region USD Million (2017-2022)
  • Table 14. Ascites CT scan , by Region USD Million (2017-2022)
  • Table 15. Ascites Others , by Region USD Million (2017-2022)
  • Table 16. Ascites: by Symptoms(USD Million)
  • Table 17. Ascites Abdominal Pain and Bloating , by Region USD Million (2017-2022)
  • Table 18. Ascites Shortness of Breath , by Region USD Million (2017-2022)
  • Table 19. Ascites Liver Failure , by Region USD Million (2017-2022)
  • Table 20. South America Ascites, by Country USD Million (2017-2022)
  • Table 21. South America Ascites, by Type USD Million (2017-2022)
  • Table 22. South America Ascites, by Application USD Million (2017-2022)
  • Table 23. South America Ascites, by Diagnosis USD Million (2017-2022)
  • Table 24. South America Ascites, by Symptoms USD Million (2017-2022)
  • Table 25. Brazil Ascites, by Type USD Million (2017-2022)
  • Table 26. Brazil Ascites, by Application USD Million (2017-2022)
  • Table 27. Brazil Ascites, by Diagnosis USD Million (2017-2022)
  • Table 28. Brazil Ascites, by Symptoms USD Million (2017-2022)
  • Table 29. Argentina Ascites, by Type USD Million (2017-2022)
  • Table 30. Argentina Ascites, by Application USD Million (2017-2022)
  • Table 31. Argentina Ascites, by Diagnosis USD Million (2017-2022)
  • Table 32. Argentina Ascites, by Symptoms USD Million (2017-2022)
  • Table 33. Rest of South America Ascites, by Type USD Million (2017-2022)
  • Table 34. Rest of South America Ascites, by Application USD Million (2017-2022)
  • Table 35. Rest of South America Ascites, by Diagnosis USD Million (2017-2022)
  • Table 36. Rest of South America Ascites, by Symptoms USD Million (2017-2022)
  • Table 37. Asia Pacific Ascites, by Country USD Million (2017-2022)
  • Table 38. Asia Pacific Ascites, by Type USD Million (2017-2022)
  • Table 39. Asia Pacific Ascites, by Application USD Million (2017-2022)
  • Table 40. Asia Pacific Ascites, by Diagnosis USD Million (2017-2022)
  • Table 41. Asia Pacific Ascites, by Symptoms USD Million (2017-2022)
  • Table 42. China Ascites, by Type USD Million (2017-2022)
  • Table 43. China Ascites, by Application USD Million (2017-2022)
  • Table 44. China Ascites, by Diagnosis USD Million (2017-2022)
  • Table 45. China Ascites, by Symptoms USD Million (2017-2022)
  • Table 46. Japan Ascites, by Type USD Million (2017-2022)
  • Table 47. Japan Ascites, by Application USD Million (2017-2022)
  • Table 48. Japan Ascites, by Diagnosis USD Million (2017-2022)
  • Table 49. Japan Ascites, by Symptoms USD Million (2017-2022)
  • Table 50. India Ascites, by Type USD Million (2017-2022)
  • Table 51. India Ascites, by Application USD Million (2017-2022)
  • Table 52. India Ascites, by Diagnosis USD Million (2017-2022)
  • Table 53. India Ascites, by Symptoms USD Million (2017-2022)
  • Table 54. South Korea Ascites, by Type USD Million (2017-2022)
  • Table 55. South Korea Ascites, by Application USD Million (2017-2022)
  • Table 56. South Korea Ascites, by Diagnosis USD Million (2017-2022)
  • Table 57. South Korea Ascites, by Symptoms USD Million (2017-2022)
  • Table 58. Taiwan Ascites, by Type USD Million (2017-2022)
  • Table 59. Taiwan Ascites, by Application USD Million (2017-2022)
  • Table 60. Taiwan Ascites, by Diagnosis USD Million (2017-2022)
  • Table 61. Taiwan Ascites, by Symptoms USD Million (2017-2022)
  • Table 62. Australia Ascites, by Type USD Million (2017-2022)
  • Table 63. Australia Ascites, by Application USD Million (2017-2022)
  • Table 64. Australia Ascites, by Diagnosis USD Million (2017-2022)
  • Table 65. Australia Ascites, by Symptoms USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Ascites, by Type USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Ascites, by Application USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Ascites, by Diagnosis USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Ascites, by Symptoms USD Million (2017-2022)
  • Table 70. Europe Ascites, by Country USD Million (2017-2022)
  • Table 71. Europe Ascites, by Type USD Million (2017-2022)
  • Table 72. Europe Ascites, by Application USD Million (2017-2022)
  • Table 73. Europe Ascites, by Diagnosis USD Million (2017-2022)
  • Table 74. Europe Ascites, by Symptoms USD Million (2017-2022)
  • Table 75. Germany Ascites, by Type USD Million (2017-2022)
  • Table 76. Germany Ascites, by Application USD Million (2017-2022)
  • Table 77. Germany Ascites, by Diagnosis USD Million (2017-2022)
  • Table 78. Germany Ascites, by Symptoms USD Million (2017-2022)
  • Table 79. France Ascites, by Type USD Million (2017-2022)
  • Table 80. France Ascites, by Application USD Million (2017-2022)
  • Table 81. France Ascites, by Diagnosis USD Million (2017-2022)
  • Table 82. France Ascites, by Symptoms USD Million (2017-2022)
  • Table 83. Italy Ascites, by Type USD Million (2017-2022)
  • Table 84. Italy Ascites, by Application USD Million (2017-2022)
  • Table 85. Italy Ascites, by Diagnosis USD Million (2017-2022)
  • Table 86. Italy Ascites, by Symptoms USD Million (2017-2022)
  • Table 87. United Kingdom Ascites, by Type USD Million (2017-2022)
  • Table 88. United Kingdom Ascites, by Application USD Million (2017-2022)
  • Table 89. United Kingdom Ascites, by Diagnosis USD Million (2017-2022)
  • Table 90. United Kingdom Ascites, by Symptoms USD Million (2017-2022)
  • Table 91. Netherlands Ascites, by Type USD Million (2017-2022)
  • Table 92. Netherlands Ascites, by Application USD Million (2017-2022)
  • Table 93. Netherlands Ascites, by Diagnosis USD Million (2017-2022)
  • Table 94. Netherlands Ascites, by Symptoms USD Million (2017-2022)
  • Table 95. Rest of Europe Ascites, by Type USD Million (2017-2022)
  • Table 96. Rest of Europe Ascites, by Application USD Million (2017-2022)
  • Table 97. Rest of Europe Ascites, by Diagnosis USD Million (2017-2022)
  • Table 98. Rest of Europe Ascites, by Symptoms USD Million (2017-2022)
  • Table 99. MEA Ascites, by Country USD Million (2017-2022)
  • Table 100. MEA Ascites, by Type USD Million (2017-2022)
  • Table 101. MEA Ascites, by Application USD Million (2017-2022)
  • Table 102. MEA Ascites, by Diagnosis USD Million (2017-2022)
  • Table 103. MEA Ascites, by Symptoms USD Million (2017-2022)
  • Table 104. Middle East Ascites, by Type USD Million (2017-2022)
  • Table 105. Middle East Ascites, by Application USD Million (2017-2022)
  • Table 106. Middle East Ascites, by Diagnosis USD Million (2017-2022)
  • Table 107. Middle East Ascites, by Symptoms USD Million (2017-2022)
  • Table 108. Africa Ascites, by Type USD Million (2017-2022)
  • Table 109. Africa Ascites, by Application USD Million (2017-2022)
  • Table 110. Africa Ascites, by Diagnosis USD Million (2017-2022)
  • Table 111. Africa Ascites, by Symptoms USD Million (2017-2022)
  • Table 112. North America Ascites, by Country USD Million (2017-2022)
  • Table 113. North America Ascites, by Type USD Million (2017-2022)
  • Table 114. North America Ascites, by Application USD Million (2017-2022)
  • Table 115. North America Ascites, by Diagnosis USD Million (2017-2022)
  • Table 116. North America Ascites, by Symptoms USD Million (2017-2022)
  • Table 117. United States Ascites, by Type USD Million (2017-2022)
  • Table 118. United States Ascites, by Application USD Million (2017-2022)
  • Table 119. United States Ascites, by Diagnosis USD Million (2017-2022)
  • Table 120. United States Ascites, by Symptoms USD Million (2017-2022)
  • Table 121. Canada Ascites, by Type USD Million (2017-2022)
  • Table 122. Canada Ascites, by Application USD Million (2017-2022)
  • Table 123. Canada Ascites, by Diagnosis USD Million (2017-2022)
  • Table 124. Canada Ascites, by Symptoms USD Million (2017-2022)
  • Table 125. Mexico Ascites, by Type USD Million (2017-2022)
  • Table 126. Mexico Ascites, by Application USD Million (2017-2022)
  • Table 127. Mexico Ascites, by Diagnosis USD Million (2017-2022)
  • Table 128. Mexico Ascites, by Symptoms USD Million (2017-2022)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Ascites: by Type(USD Million)
  • Table 140. Ascites Exudate Ascites , by Region USD Million (2023-2028)
  • Table 141. Ascites Transudative Ascites , by Region USD Million (2023-2028)
  • Table 142. Ascites: by Application(USD Million)
  • Table 143. Ascites Hospitals , by Region USD Million (2023-2028)
  • Table 144. Ascites Clinics , by Region USD Million (2023-2028)
  • Table 145. Ascites Ambulatory Surgical Centers , by Region USD Million (2023-2028)
  • Table 146. Ascites Diagnostics Centers , by Region USD Million (2023-2028)
  • Table 147. Ascites Others , by Region USD Million (2023-2028)
  • Table 148. Ascites: by Diagnosis(USD Million)
  • Table 149. Ascites Angiography , by Region USD Million (2023-2028)
  • Table 150. Ascites Ultrasound , by Region USD Million (2023-2028)
  • Table 151. Ascites Laparoscopy , by Region USD Million (2023-2028)
  • Table 152. Ascites CT scan , by Region USD Million (2023-2028)
  • Table 153. Ascites Others , by Region USD Million (2023-2028)
  • Table 154. Ascites: by Symptoms(USD Million)
  • Table 155. Ascites Abdominal Pain and Bloating , by Region USD Million (2023-2028)
  • Table 156. Ascites Shortness of Breath , by Region USD Million (2023-2028)
  • Table 157. Ascites Liver Failure , by Region USD Million (2023-2028)
  • Table 158. South America Ascites, by Country USD Million (2023-2028)
  • Table 159. South America Ascites, by Type USD Million (2023-2028)
  • Table 160. South America Ascites, by Application USD Million (2023-2028)
  • Table 161. South America Ascites, by Diagnosis USD Million (2023-2028)
  • Table 162. South America Ascites, by Symptoms USD Million (2023-2028)
  • Table 163. Brazil Ascites, by Type USD Million (2023-2028)
  • Table 164. Brazil Ascites, by Application USD Million (2023-2028)
  • Table 165. Brazil Ascites, by Diagnosis USD Million (2023-2028)
  • Table 166. Brazil Ascites, by Symptoms USD Million (2023-2028)
  • Table 167. Argentina Ascites, by Type USD Million (2023-2028)
  • Table 168. Argentina Ascites, by Application USD Million (2023-2028)
  • Table 169. Argentina Ascites, by Diagnosis USD Million (2023-2028)
  • Table 170. Argentina Ascites, by Symptoms USD Million (2023-2028)
  • Table 171. Rest of South America Ascites, by Type USD Million (2023-2028)
  • Table 172. Rest of South America Ascites, by Application USD Million (2023-2028)
  • Table 173. Rest of South America Ascites, by Diagnosis USD Million (2023-2028)
  • Table 174. Rest of South America Ascites, by Symptoms USD Million (2023-2028)
  • Table 175. Asia Pacific Ascites, by Country USD Million (2023-2028)
  • Table 176. Asia Pacific Ascites, by Type USD Million (2023-2028)
  • Table 177. Asia Pacific Ascites, by Application USD Million (2023-2028)
  • Table 178. Asia Pacific Ascites, by Diagnosis USD Million (2023-2028)
  • Table 179. Asia Pacific Ascites, by Symptoms USD Million (2023-2028)
  • Table 180. China Ascites, by Type USD Million (2023-2028)
  • Table 181. China Ascites, by Application USD Million (2023-2028)
  • Table 182. China Ascites, by Diagnosis USD Million (2023-2028)
  • Table 183. China Ascites, by Symptoms USD Million (2023-2028)
  • Table 184. Japan Ascites, by Type USD Million (2023-2028)
  • Table 185. Japan Ascites, by Application USD Million (2023-2028)
  • Table 186. Japan Ascites, by Diagnosis USD Million (2023-2028)
  • Table 187. Japan Ascites, by Symptoms USD Million (2023-2028)
  • Table 188. India Ascites, by Type USD Million (2023-2028)
  • Table 189. India Ascites, by Application USD Million (2023-2028)
  • Table 190. India Ascites, by Diagnosis USD Million (2023-2028)
  • Table 191. India Ascites, by Symptoms USD Million (2023-2028)
  • Table 192. South Korea Ascites, by Type USD Million (2023-2028)
  • Table 193. South Korea Ascites, by Application USD Million (2023-2028)
  • Table 194. South Korea Ascites, by Diagnosis USD Million (2023-2028)
  • Table 195. South Korea Ascites, by Symptoms USD Million (2023-2028)
  • Table 196. Taiwan Ascites, by Type USD Million (2023-2028)
  • Table 197. Taiwan Ascites, by Application USD Million (2023-2028)
  • Table 198. Taiwan Ascites, by Diagnosis USD Million (2023-2028)
  • Table 199. Taiwan Ascites, by Symptoms USD Million (2023-2028)
  • Table 200. Australia Ascites, by Type USD Million (2023-2028)
  • Table 201. Australia Ascites, by Application USD Million (2023-2028)
  • Table 202. Australia Ascites, by Diagnosis USD Million (2023-2028)
  • Table 203. Australia Ascites, by Symptoms USD Million (2023-2028)
  • Table 204. Rest of Asia-Pacific Ascites, by Type USD Million (2023-2028)
  • Table 205. Rest of Asia-Pacific Ascites, by Application USD Million (2023-2028)
  • Table 206. Rest of Asia-Pacific Ascites, by Diagnosis USD Million (2023-2028)
  • Table 207. Rest of Asia-Pacific Ascites, by Symptoms USD Million (2023-2028)
  • Table 208. Europe Ascites, by Country USD Million (2023-2028)
  • Table 209. Europe Ascites, by Type USD Million (2023-2028)
  • Table 210. Europe Ascites, by Application USD Million (2023-2028)
  • Table 211. Europe Ascites, by Diagnosis USD Million (2023-2028)
  • Table 212. Europe Ascites, by Symptoms USD Million (2023-2028)
  • Table 213. Germany Ascites, by Type USD Million (2023-2028)
  • Table 214. Germany Ascites, by Application USD Million (2023-2028)
  • Table 215. Germany Ascites, by Diagnosis USD Million (2023-2028)
  • Table 216. Germany Ascites, by Symptoms USD Million (2023-2028)
  • Table 217. France Ascites, by Type USD Million (2023-2028)
  • Table 218. France Ascites, by Application USD Million (2023-2028)
  • Table 219. France Ascites, by Diagnosis USD Million (2023-2028)
  • Table 220. France Ascites, by Symptoms USD Million (2023-2028)
  • Table 221. Italy Ascites, by Type USD Million (2023-2028)
  • Table 222. Italy Ascites, by Application USD Million (2023-2028)
  • Table 223. Italy Ascites, by Diagnosis USD Million (2023-2028)
  • Table 224. Italy Ascites, by Symptoms USD Million (2023-2028)
  • Table 225. United Kingdom Ascites, by Type USD Million (2023-2028)
  • Table 226. United Kingdom Ascites, by Application USD Million (2023-2028)
  • Table 227. United Kingdom Ascites, by Diagnosis USD Million (2023-2028)
  • Table 228. United Kingdom Ascites, by Symptoms USD Million (2023-2028)
  • Table 229. Netherlands Ascites, by Type USD Million (2023-2028)
  • Table 230. Netherlands Ascites, by Application USD Million (2023-2028)
  • Table 231. Netherlands Ascites, by Diagnosis USD Million (2023-2028)
  • Table 232. Netherlands Ascites, by Symptoms USD Million (2023-2028)
  • Table 233. Rest of Europe Ascites, by Type USD Million (2023-2028)
  • Table 234. Rest of Europe Ascites, by Application USD Million (2023-2028)
  • Table 235. Rest of Europe Ascites, by Diagnosis USD Million (2023-2028)
  • Table 236. Rest of Europe Ascites, by Symptoms USD Million (2023-2028)
  • Table 237. MEA Ascites, by Country USD Million (2023-2028)
  • Table 238. MEA Ascites, by Type USD Million (2023-2028)
  • Table 239. MEA Ascites, by Application USD Million (2023-2028)
  • Table 240. MEA Ascites, by Diagnosis USD Million (2023-2028)
  • Table 241. MEA Ascites, by Symptoms USD Million (2023-2028)
  • Table 242. Middle East Ascites, by Type USD Million (2023-2028)
  • Table 243. Middle East Ascites, by Application USD Million (2023-2028)
  • Table 244. Middle East Ascites, by Diagnosis USD Million (2023-2028)
  • Table 245. Middle East Ascites, by Symptoms USD Million (2023-2028)
  • Table 246. Africa Ascites, by Type USD Million (2023-2028)
  • Table 247. Africa Ascites, by Application USD Million (2023-2028)
  • Table 248. Africa Ascites, by Diagnosis USD Million (2023-2028)
  • Table 249. Africa Ascites, by Symptoms USD Million (2023-2028)
  • Table 250. North America Ascites, by Country USD Million (2023-2028)
  • Table 251. North America Ascites, by Type USD Million (2023-2028)
  • Table 252. North America Ascites, by Application USD Million (2023-2028)
  • Table 253. North America Ascites, by Diagnosis USD Million (2023-2028)
  • Table 254. North America Ascites, by Symptoms USD Million (2023-2028)
  • Table 255. United States Ascites, by Type USD Million (2023-2028)
  • Table 256. United States Ascites, by Application USD Million (2023-2028)
  • Table 257. United States Ascites, by Diagnosis USD Million (2023-2028)
  • Table 258. United States Ascites, by Symptoms USD Million (2023-2028)
  • Table 259. Canada Ascites, by Type USD Million (2023-2028)
  • Table 260. Canada Ascites, by Application USD Million (2023-2028)
  • Table 261. Canada Ascites, by Diagnosis USD Million (2023-2028)
  • Table 262. Canada Ascites, by Symptoms USD Million (2023-2028)
  • Table 263. Mexico Ascites, by Type USD Million (2023-2028)
  • Table 264. Mexico Ascites, by Application USD Million (2023-2028)
  • Table 265. Mexico Ascites, by Diagnosis USD Million (2023-2028)
  • Table 266. Mexico Ascites, by Symptoms USD Million (2023-2028)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ascites: by Type USD Million (2017-2022)
  • Figure 5. Global Ascites: by Application USD Million (2017-2022)
  • Figure 6. Global Ascites: by Diagnosis USD Million (2017-2022)
  • Figure 7. Global Ascites: by Symptoms USD Million (2017-2022)
  • Figure 8. South America Ascites Share (%), by Country
  • Figure 9. Asia Pacific Ascites Share (%), by Country
  • Figure 10. Europe Ascites Share (%), by Country
  • Figure 11. MEA Ascites Share (%), by Country
  • Figure 12. North America Ascites Share (%), by Country
  • Figure 13. Global Ascites share by Players 2022 (%)
  • Figure 14. Global Ascites share by Players (Top 3) 2022(%)
  • Figure 15. Global Ascites share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Sofinnova (United States) Revenue, Net Income and Gross profit
  • Figure 18. Sofinnova (United States) Revenue: by Geography 2022
  • Figure 19. PharmaCyte (United States) Revenue, Net Income and Gross profit
  • Figure 20. PharmaCyte (United States) Revenue: by Geography 2022
  • Figure 21. Biotech Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Biotech Inc. (United States) Revenue: by Geography 2022
  • Figure 23. Sequana Medical NV (Belgium) Revenue, Net Income and Gross profit
  • Figure 24. Sequana Medical NV (Belgium) Revenue: by Geography 2022
  • Figure 25. BioVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. BioVie Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Becton (United States) Revenue, Net Income and Gross profit
  • Figure 28. Becton (United States) Revenue: by Geography 2022
  • Figure 29. Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 30. Dickinson and Company (United States) Revenue: by Geography 2022
  • Figure 31. GI Supply (United States) Revenue, Net Income and Gross profit
  • Figure 32. GI Supply (United States) Revenue: by Geography 2022
  • Figure 33. QED Bioscience Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. QED Bioscience Inc. (United States) Revenue: by Geography 2022
  • Figure 35. Fresenius SE & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Fresenius SE & Co. KGaA (Germany) Revenue: by Geography 2022
  • Figure 37. Global Ascites: by Type USD Million (2023-2028)
  • Figure 38. Global Ascites: by Application USD Million (2023-2028)
  • Figure 39. Global Ascites: by Diagnosis USD Million (2023-2028)
  • Figure 40. Global Ascites: by Symptoms USD Million (2023-2028)
  • Figure 41. South America Ascites Share (%), by Country
  • Figure 42. Asia Pacific Ascites Share (%), by Country
  • Figure 43. Europe Ascites Share (%), by Country
  • Figure 44. MEA Ascites Share (%), by Country
  • Figure 45. North America Ascites Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sofinnova (United States)
  • PharmaCyte (United States)
  • Biotech Inc. (United States)
  • Sequana Medical NV (Belgium)
  • BioVie Inc. (United States)
  • Becton (United States)
  • Dickinson and Company (United States)
  • GI Supply (United States)
  • QED Bioscience Inc. (United States)
  • Fresenius SE & Co. KGaA (Germany)
Additional players considered in the study are as follows:
Abcore, Inc. (United States) , Chiba University (Japan) , Masonic Cancer Center (United States)
Select User Access Type

Key Highlights of Report


May 2023 231 Pages 59 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Ascites Market Quantitative research analysis
Global Ascites Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 201-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Ascites Market are Sofinnova (United States), PharmaCyte (United States), Biotech Inc. (United States), Sequana Medical NV (Belgium), BioVie Inc. (United States), Becton (United States), Dickinson and Company (United States), GI Supply (United States), QED Bioscience Inc. (United States) and Fresenius SE & Co. KGaA (Germany) etc.
Hospitals segment in Global market to hold robust market share owing to "Rise in Prevalence of Liver Cirrhosis ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Ascites market throughout the forecasted period.

Know More About Global Ascites Market Report?

Have a Query? Click Here

Other Related Reports

Acute Intermittent Porphyria Comprehensive Study by Treatment (Gonadotropin-Releasing Hormone Analogues, Prophylactic Hematin Infusions, Others), Diagnosis (Blood Test, Urine Test, DNA Test, Serum Te...
$ 3450
Neurodegenerative Diseases Comprehensive Study by Application (Alzheimer's Disease, Huntington Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis), Drug Type (N-methyl-D-aspartate Receptor, ...
$ 3450
New Generation Implants Comprehensive Study by Type (Endosteal,, Subperiosteal,, Zygomatic.), Application (Orthopedic Implants, Cardiovascular Implants, Ocular Implants, Dental Implants), Raw Materia...
$ 3500
Bartter Syndrome Treatment Comprehensive Study by Type (Medication, Therapy), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Genes Types (LC12A1 Gene, KCNJ1 Gene, CLCNKB Gen...
$ 3750
Nasopharyngeal Cancer Comprehensive Study by Type (Keratinizing Squamous Cell Carcinoma, Nonkeratinizing Squamous Cell Carcinoma, Undifferentiated or Poorly Differentiated), Application (Hospitals, C...
$ 3650
Pituitary cancer Comprehensive Study by Type (Surgery, Endoscopic Transnasal Transsphenoidal Surgery, Craniotomy, Radiation Therapy, Stereotactic Radiosurgery, External beam radiation, Intensity Modu...
$ 3750